Back to Search
Start Over
Province-to-province variability in hepatitis C testing, care, and treatment across Canada.
- Source :
-
Canadian liver journal [Can Liver J] 2023 Jul 26; Vol. 6 (2), pp. 234-248. Date of Electronic Publication: 2023 Jul 26 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Background: Few countries have implemented the necessary policy changes to reduce the number of steps in the cascade of care to achieve hepatitis C virus (HCV) elimination, including Canada. The aim of this study was to describe and compare legislation, scope of practice, and policy as it relates to the provision of HCV care in each province.<br />Methods: We reviewed grey literature and regulatory and legislative documents which affect various aspects of the HCV cascade of care. Findings were verified by content experts.<br />Results: HCV RNA reflex testing ensures those that are antibody positive get an HCV RNA test; however only 80% of provinces have reflex test. Point-of-care antibody testing can be offered in most community non-health care settings, yet many types of health care providers are unable to do this independently. Following a positive test, it may not be feasible to complete venipuncture; however only a single province processes HCV RNA dried blood spot cards. In many provinces, training and verification are required for novice prescribers, and in some provinces prescribing continues to be restricted to specialists. Only a single province has task-shifted treatment to a non-physician non-nurse practitioner model, where pharmacists can prescribe treatment. Finally, 80% of provinces require authorization forms, and 30% require proof of investigations for treatment.<br />Conclusions: No single province is optimizing the use of diagnostic tools and task shifting and decreasing paperwork to expedite treatment initiation. Collaboration between provinces is needed to streamline practice, update policy, and promote equity in HCV diagnosis, care, and treatment.<br />Competing Interests: MJ Biondi reports receiving research support and consulting fees from AbbVie, Gilead, and Specialty Rx Solutions. CH Dale is a paid employee of McKesson Canada, and receives consulting fees from AbbVie and Gilead. H Shah reports receiving consulting fees and research support from AbbVie and Gilead. JJ Feld reports receiving research support and consulting fees from AbbVie and Gilead. HLA Janssen reports receiving research support from AbbVie and Gilead. The other authors have nothing to disclose.<br /> (© Canadian Association for the Study of the Liver, 2023.)
Details
- Language :
- English
- ISSN :
- 2561-4444
- Volume :
- 6
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Canadian liver journal
- Publication Type :
- Academic Journal
- Accession number :
- 37503520
- Full Text :
- https://doi.org/10.3138/canlivj-2022-0029